Viva Biotech Holdings (HKSE:01873) FCF Margin % : -1.98% (As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Viva Biotech Holdings FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Viva Biotech Holdings's Free Cash Flow for the six months ended in Dec. 2023 was HK$-22 Mil. Viva Biotech Holdings's Revenue for the six months ended in Dec. 2023 was HK$1,108 Mil. Therefore, Viva Biotech Holdings's FCF Margin % for the quarter that ended in Dec. 2023 was -1.98%.

As of today, Viva Biotech Holdings's current FCF Yield % is 15.37%.

The historical rank and industry rank for Viva Biotech Holdings's FCF Margin % or its related term are showing as below:

HKSE:01873' s FCF Margin % Range Over the Past 10 Years
Min: -82.46 Med: 0.42 Max: 14.28
Current: 9.07

During the past 8 years, the highest FCF Margin % of Viva Biotech Holdings was 14.28%. The lowest was -82.46%. And the median was 0.42%.

HKSE:01873's FCF Margin % is ranked better than
86.59% of 1044 companies
in the Biotechnology industry
Industry Median: -141.025 vs HKSE:01873: 9.07

Viva Biotech Holdings FCF Margin % Historical Data

The historical data trend for Viva Biotech Holdings's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Viva Biotech Holdings FCF Margin % Chart

Viva Biotech Holdings Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

-4.90

-82.46

-23.22

5.74

9.07

Viva Biotech Holdings Semi-Annual Data
	Dec16	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
FCF Margin %	Get a 7-Day Free Trial									-26.45	-3.97	14.21	18.88	-1.98

Competitive Comparison of Viva Biotech Holdings's FCF Margin %

For the Biotechnology subindustry, Viva Biotech Holdings's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Viva Biotech Holdings's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Viva Biotech Holdings's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Viva Biotech Holdings's FCF Margin % falls into.

Viva Biotech Holdings FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Viva Biotech Holdings's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	213.909	/	2357.726
	=	9.07 %

Viva Biotech Holdings's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-22.001	/	1108.429
	=	-1.98 %

Viva Biotech Holdings FCF Margin % Related Terms

Thank you for viewing the detailed overview of Viva Biotech Holdings's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Viva Biotech Holdings (HKSE:01873) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Viva Biotech Holdings (HKSE:01873) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

VBIZF:USA VB0:Germany

Address

735 Ziping Road, Pudong New District, Zhoupu Town, Shanghai, CHN, 201318

Website

https://www.vivabiotech.com

Viva Biotech Holdings is an integrated drug discovery platform. The company's operating segment includes Drug discovery services and Contract Development Manufacture Organisation (CDMO) and commercialisation services. It generates maximum revenue from the Contract Development Manufacture Organisation (CDMO) and commercialisation services segment. The Contract Development Manufacture Organisation ("CDMO") and commercialisation services segment includes contract development and manufacturing services for small molecule APIs and intermediates and trading of APIs, intermediates and formulations.

Executives

Mao Chen Cheney	2101 Beneficial owner
Wu John Jiong	2201 Interest of corporation controlled by you
Fenghe Harvest Ltd	2101 Beneficial owner
Jpmorgan Chase & Co.	2201 Interest of corporation controlled by you
Mao Jun	2501 Other
Temasek Holdings (private) Limited	2201 Interest of corporation controlled by you
Zhou Min	2202 Interest of your spouse
Intertrust (singapore) Ltd.	2301 Trustee
Z&m International Holdings Limited	2201 Interest of corporation controlled by you
Zhang And Sons Limited	2101 Beneficial owner

Viva Biotech Holdings (HKSE:01873) Headlines

No Headlines